ImmunityBio (IBRX)
8.64
-0.13 (1.48%)
Upcoming Events
Latest Headlines
ImmunityBio locks database for bladder cancer trial, eyes 2026 results
October 21, 2026 7:33 AM - StreetInsider
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
October 21, 2026 7:30 AM - BizWire
ImmunityBio reports 3-year bladder preservation data for Anktiva plus BCG
October 16, 2026 11:49 AM - StreetInsider
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Pap
October 16, 2026 11:49 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
October 15, 2026 6:57 AM - StreetInsider
Form 8-K ImmunityBio, Inc. For: Oct 14
October 14, 2026 5:19 PM - SEC Filing
Immunitybio Inc (IBRX) PT Raised to $14 at Jefferies
October 14, 2026 4:34 PM - StreetInsider
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
October 14, 2026 4:18 PM - BizWire
FDA expands Anktiva approval to include papillary-only bladder cancer
October 14, 2026 11:20 AM - StreetInsider
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
October 8, 2026 8:30 AM - BizWire
Form 4 ImmunityBio, Inc. For: Oct 05 Filed by: Simon Barry J.
October 6, 2026 6:06 PM - SEC Filing
Form 4 ImmunityBio, Inc. For: Oct 02 Filed by: Cohen Cheryl
October 6, 2026 6:06 PM - SEC Filing
Form 144 ImmunityBio, Inc. Filed by: Simon Barry J.
October 5, 2026 10:22 AM - SEC Filing
Form 144 ImmunityBio, Inc. Filed by: Cohen Cheryl
October 2, 2026 4:27 PM - SEC Filing
These High-Voltage Stocks Are Suddenly Impossible to Ignore
October 2, 2026 11:45 AM - StreetInsider
PDS Biotech closes $11.3M PIPE led by Nant Capital, adds Soon-Shiong
September 14, 2026 10:30 AM - StreetInsider
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
September 14, 2026 10:30 AM - StreetInsider
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
September 1, 2026 9:07 AM - StreetInsider
ImmunityBio names former World Bank president Jim Yong Kim as vice chairman
August 10, 2026 9:01 AM - StreetInsider
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
August 10, 2026 9:00 AM - BizWire
Form SCHEDULE 13D/A ImmunityBio, Inc. Filed by: Cambridge Equities, LP
August 6, 2026 6:51 PM - SEC Filing
Form 10-Q ImmunityBio, Inc. For: Jun 30
August 4, 2026 7:46 AM - SEC Filing
ImmunityBio, Inc. (IBRX) Misses Q2 EPS by 14c
August 4, 2026 7:38 AM - StreetInsider
Form 8-K ImmunityBio, Inc. For: Aug 04
August 4, 2026 7:36 AM - SEC Filing
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
August 4, 2026 7:30 AM - BizWire
Form 8-K ImmunityBio, Inc. For: Jul 29
July 30, 2026 5:20 PM - SEC Filing
UAE approves ImmunityBio's Anktiva for bladder and lung cancer
July 30, 2026 4:53 AM - StreetInsider
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small
July 29, 2026 6:45 PM - BizWire
Full Article List
